CFTR inactivation by lentiviral vector-mediated RNA interference and CRISPR-Cas9 genome editing in human airway epithelial cells.

作者: Jessica Bellec , Marc Bacchetta , Davide Losa , Ignacio Anegon , Marc Chanson

DOI: 10.2174/1566523215666150812115939

关键词:

摘要: Background: Polarized airway epithelial cell cultures modelling Cystic Fibrosis Transmembrane conductance Regulator ( CFTR ) defect are crucial for CF and biomedical research. RNA interference has proven its value to generate knockdown models various pathologies. More recently, genome editing using CRISPR-Cas9 artificial endonuclease was a valuable addition the toolbox of gene inactivation. Methods: Calu-3 cells primary HAECs were transduced with HIV-1-derived lentiviral vectors (LVV) encoding small hairpin (shRNA) sequence or components targeting alongside GFP. After sorting of GFP-positive cells, expression measured by RT-qPCR and Western blot in polarized differentiated cells. channel function assessed Ussing chambers. Il-8 secretion, proliferation migration also studied Results: shRNA interference CRISPRCas9 strategies efficiently decreased Strong confirmed at the functional level CRISPR-Cas9-modified -specific sequences did not reduce gene primary HAECs, whereas CRISPR-Cas9-mediated modification activity correlated reduction transepithelial secretion response inhibitor. inactivation affect migration proliferation but slightly increased basal interleukin-8 secretion. Conclusion: We generated CFTRinactivated cell lines demonstrated that vectorised single LVV promotes inactivation in HAECs. These results provide new protocol engineer epithelia their isogenic controls and pave way manipulation these cultures.

参考文章(55)
L J MacVinish, G Cope, A Ropenga, A W Cuthbert, Chloride transporting capability of Calu-3 epithelia following persistent knockdown of the cystic fibrosis transmembrane conductance regulator, CFTR British Journal of Pharmacology. ,vol. 150, pp. 1055- 1065 ,(2007) , 10.1038/SJ.BJP.0707175
Jamil Aarbiou, Elena Copreni, Ruvalic M. Buijs-Offerman, Pascal van der Wegen, Stefano Castellani, Annalucia Carbone, Francesca Tilesi, Piera Fradiani, Pieter S. Hiemstra, Guelnihal Yueksekdag, Anna Diana, Joseph Rosenecker, Fiorentina Ascenzioni, Massimo Conese, Bob J. Scholte, Lentiviral small hairpin RNA delivery reduces apical sodium channel activity in differentiated human airway epithelial cells Journal of Gene Medicine. ,vol. 14, pp. 733- 745 ,(2012) , 10.1002/JGM.2672
L G Johnson, J C Olsen, L Naldini, R C Boucher, Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo Gene Therapy. ,vol. 7, pp. 568- 574 ,(2000) , 10.1038/SJ.GT.3301138
Lee A. Borthwick, Phil Botha, Bernard Verdon, Malcolm J. Brodlie, Aaron Gardner, David Bourn, Gail E. Johnson, Mike A. Gray, Andrew J. Fisher, Is CFTR-delF508 Really Absent from the Apical Membrane of the Airway Epithelium? PLoS ONE. ,vol. 6, pp. e23226- ,(2011) , 10.1371/JOURNAL.PONE.0023226
Mi Cai, Yi Yang, Targeted genome editing tools for disease modeling and gene therapy. Current Gene Therapy. ,vol. 14, pp. 2- 9 ,(2014) , 10.2174/156652321402140318165450
Xingshen Sun, Hongshu Sui, John T. Fisher, Ziying Yan, Xiaoming Liu, Hyung-Ju Cho, Nam Soo Joo, Yulong Zhang, Weihong Zhou, Yaling Yi, Joann M. Kinyon, Diana C. Lei-Butters, Michelle A. Griffin, Paul Naumann, Meihui Luo, Jill Ascher, Kai Wang, Timothy Frana, Jeffrey J. Wine, David K. Meyerholz, John F. Engelhardt, Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis Journal of Clinical Investigation. ,vol. 120, pp. 3149- 3160 ,(2010) , 10.1172/JCI43052
Ben Forbes, Carsten Ehrhardt, Human respiratory epithelial cell culture for drug delivery applications. European Journal of Pharmaceutics and Biopharmaceutics. ,vol. 60, pp. 193- 205 ,(2005) , 10.1016/J.EJPB.2005.02.010
Indu Pal Kaur, Kanwaljit Chopra, Parveen Rishi, Sanjeev Puri, Gaurav Sharma, Small RNAs: the qualified candidates for gene manipulation in diverse clinical pathologies. Critical Reviews in Therapeutic Drug Carrier Systems. ,vol. 31, pp. 305- 329 ,(2014) , 10.1615/CRITREVTHERDRUGCARRIERSYST.2014007943